|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CD163 |
Gene summary for CD163 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CD163 | Gene ID | 9332 |
| Gene name | CD163 molecule | |
| Gene Alias | M130 | |
| Cytomap | 12p13.31 | |
| Gene Type | protein-coding | GO ID | GO:0002526 | UniProtAcc | Q86VB7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9332 | CD163 | HCC1_Meng | Human | Liver | HCC | 8.69e-25 | 7.25e-02 | 0.0246 |
| 9332 | CD163 | HCC1 | Human | Liver | HCC | 3.33e-04 | 5.06e-01 | 0.5336 |
| 9332 | CD163 | Pt13.a | Human | Liver | HCC | 3.13e-05 | 2.34e-01 | 0.021 |
| 9332 | CD163 | Pt13.c | Human | Liver | HCC | 6.33e-12 | 6.58e-01 | 0.0076 |
| 9332 | CD163 | Pt14.d | Human | Liver | HCC | 3.53e-21 | 5.72e-01 | 0.0143 |
| 9332 | CD163 | S028 | Human | Liver | HCC | 8.28e-07 | 2.13e-01 | 0.2503 |
| 9332 | CD163 | S029 | Human | Liver | HCC | 4.49e-03 | 3.13e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
| GO:00069532 | Liver | HCC | acute-phase response | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CD163 | SNV | Missense_Mutation | novel | c.3358N>C | p.Ser1120Pro | p.S1120P | Q86VB7 | protein_coding | tolerated(0.29) | benign(0.184) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
| CD163 | SNV | Missense_Mutation | c.877G>A | p.Asp293Asn | p.D293N | Q86VB7 | protein_coding | tolerated(0.22) | possibly_damaging(0.841) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| CD163 | SNV | Missense_Mutation | novel | c.1459N>C | p.Cys487Arg | p.C487R | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| CD163 | SNV | Missense_Mutation | rs373039092 | c.1750N>T | p.Arg584Cys | p.R584C | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CD163 | SNV | Missense_Mutation | rs181334925 | c.535C>T | p.Arg179Trp | p.R179W | Q86VB7 | protein_coding | deleterious(0.01) | possibly_damaging(0.606) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD |
| CD163 | insertion | In_Frame_Ins | novel | c.1983_1984insGCAATGGAAAAGAATCCCGCATTTGGCAGTGCC | p.Asp661_Cys662insAlaMetGluLysAsnProAlaPheGlySerAla | p.D661_C662insAMEKNPAFGSA | Q86VB7 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| CD163 | insertion | Nonsense_Mutation | novel | c.573_574insGTTACATACCAAACAGTGTACCAGTAGTTTTA | p.His192ValfsTer9 | p.H192Vfs*9 | Q86VB7 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| CD163 | SNV | Missense_Mutation | c.1754N>G | p.Leu585Trp | p.L585W | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CD163 | SNV | Missense_Mutation | c.3302N>T | p.Ser1101Phe | p.S1101F | Q86VB7 | protein_coding | tolerated(0.27) | possibly_damaging(0.896) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| CD163 | SNV | Missense_Mutation | c.1547N>A | p.Cys516Tyr | p.C516Y | Q86VB7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9332 | CD163 | DRUGGABLE GENOME, KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | GLUCOCORTICOID | 9712057 | ||
| 9332 | CD163 | DRUGGABLE GENOME, KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE | FLUTICASONE PROPIONATE | 9712057 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |